Morgan Stanley says these two “strong buy” stocks might double in value from here.

Morgan Stanley asked two months earlier, “Will the September market fall take longer than typical to recover?” “Fast forward to today, and the answer to that question is a definite no,” says the firm’s chief US stock analyst Mike Wilson. Instead, our statistics reveal that individual investors are sticking to their guns when it comes to buying stocks…”

Wilson believes that regular investors are fueling the market’s current upward momentum, and that, ironically, the threat of terrible times is pushing them. Retail investors are moving into stocks as a defensive measure, according to Wilson, because they recognize that in the present economic context of increasing inflation and low interest rates, high-performance equities give some safety for investment portfolios.

With this in mind, we decided to take a deeper look at two stocks that have just earned Morgan Stanley’s approval, with the company estimating more than 100% upside potential for each. Using TipRanks’ database, we discovered that the rest of Wall Street is on board as well, with both stocks receiving a “Strong Buy” consensus rating.

Taysha Gene Therapies (TSHA)

Let’s start with Taysha Gene Therapies, a biopharmaceutical business situated in Texas. This firm is dedicated…